Comprehensive Strategy to Decolonize Methicillin-resistant Staphylococcus Aureus (MRSA) in the Outpatient Setting
NCT ID: NCT01232231
Last Updated: 2013-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2010-07-31
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Natural History of Community-Associated MRSA Infections and Decolonization Strategies
NCT00513799
Randomized Controlled Trial of Standard Versus Systemic Decolonization Therapy for the Eradication of Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization
NCT01438515
Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
NCT01209234
Staphylococcus Aureus Decolonization Study
NCT00731783
A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients
NCT01234831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
decolonization treatment
topical antiseptic, intranasal antimicrobial, and oral antimicrobial that have activity against MRSA in addition to education regarding personal hygiene and environmental cleaning
pharmacological decolonization treatment
Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
education
No decolonization treatment in addition to education regarding personal hygiene and environmental cleaning
Education
No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
pharmacological decolonization treatment
Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
Education
No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Identified as being colonized with MRSA on initial screen
Exclusion Criteria
* Have indwelling catheters.
* Received prior decolonization treatment within last 6 months of enrollment.
* Have allergy to study medication.
* Are colonized with MRSA strain resistant to study medication.
* Have active infection requiring systemic antimicrobials.
* Are household contacts to index case.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alberta Health services
OTHER
Joseph Kim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Joseph Kim
Clinical Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Thomas J Louie, MD
Role: PRINCIPAL_INVESTIGATOR
University of Calgary
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Foothills Medical Center
Calgary, Alberta, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E23134
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.